Eun Joo Kang

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Jang Ho Cho, Sung Hee Lim, Ho Jung An et al. · Journal of Clinical Oncology · 2019 · 346 citations · Full text

Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients

E. J. Kim, S. S. Cho, Yong Jeong et al. · Brain · 2005 · 231 citations · Full text

Aging, Neurochemical Biomarkers, Late Onset +21

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Sehhoon Park, Tae Min Kim, Ji‐Youn Han et al. · Journal of Clinical Oncology · 2023 · 141 citations · Full text

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)

Yun‐Gyoo Lee, Eun Joo Kang, Bhumsuk Keam et al. · BMC Cancer · 2020 · 68 citations · Full text